Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

On January 27, 2025 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported positive interim data from multiple clinical trials, including safety and feasibility studies treating patients with pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials (Press release, Alpha Tau Medical, JAN 27, 2025, View Source [SID1234649881]). The data will be shared during an R&D Update Day to be held today at 11am ET; registration for the event and further information are available at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pancreatic Cancer Trials – Interim Data as of Jan 8, 2025

Across three ongoing feasibility and safety trials, two in Canada and one in Israel, 41 patients with pancreatic cancer had been treated with Alpha DaRT in Canada (n=24) and Israel (n=17), including the first five patients for whom interim data was already released in late 2023. A 100% success rate was achieved in delivering the Alpha DaRT sources (feasibility), and strong safety results were observed: 151 adverse events were reported in total, of which 38 were possibly, probably or definitely associated with Alpha DaRT treatment, of which three were deemed serious adverse events (SAEs). Two of three SAEs required brief hospitalizations and all patients were discharged or recovered.

Among the 41 patients across the three trials, 33 patients had a measured objective response and were examined for survival metrics.

Using best overall response (BOR) in patients with a measured response, the findings from a pooled analysis include:

● 18% objective response rate, or ORR (either a complete response or partial response) and 91% disease control rate, or DCR (complete response, partial response or stable disease)

● Excluding the first two patients, who were deliberately given low dosages in order to determine feasibility and safety only, analysis demonstrated a 19% ORR and 97% DCR– with only one patient experiencing progressive disease

Using Kaplan-Meier statistics for measurement of overall survival (OS), median OS across all 33 patients was 18.6 months after diagnosis or initiation of the previous round of chemotherapy, or 10.9 months after treatment with Alpha DaRT.

Ad-hoc analyses of key sub-populations evaluated in the Company’s pancreatic cancer trials vs. results from relevant third-party clinical studies illustrate the potential benefit of Alpha DaRT for patient populations with generally poor prognoses, though caution should be exercised in comparing results from unrelated clinical studies due to differences in study designs, patient populations and other relevant factors. Findings from the Company’s ad-hoc analyses include:

● For patients who could not or would not receive chemotherapy (n=8), patients treated with Alpha DaRT demonstrated median OS of 7.5 months after diagnosis, with four of eight treated patients still alive, compared to third-party studies1,2 suggesting that expected baseline survival with untreated pancreatic cancer is approximately 3 – 3.5 months.

● For metastatic patients whose cancer progressed after receiving first-line FOLFIRINOX chemotherapy (n=10), median OS was not yet reached after 15.1 months of median overall follow-up since the initiation of FOLFIRINOX, with eight of ten treated patients still alive, compared to historical studies3,4,5 demonstrating median OS of 10.1 – 11.1 months from the initiation of first-line FOLFIRINOX in metastatic patients.

● For patients whose cancer progressed after receiving second-line Gemcitabine-Abraxane chemotherapy (n=7), findings show a median OS of 23.0 months since the initiation of Gemcitabine-Abraxane, and a median OS of 9.0 months since being treated with Alpha DaRT, with three of seven treated patients still alive, compared to historical studies6,7,8 demonstrating median OS of 7.6 – 9.9 months from the initiation of second-line Gemcitabine-Abraxane.

In today’s presentation, the clinicians will discuss the clinician and patient experience with Alpha DaRT for pancreatic cancer, and will also review the case study of a patient who was treated with Alpha DaRT concurrently with chemotherapy for pancreatic adenocarcinoma with liver metastases and who had a complete resolution on PET scan at 90 days of both the primary tumor and the liver metastases.

Approval for pancreatic cancer clinical trials in U.S. and France

The Company has also announced the receipt of an IDE from the U.S. Food and Drug Administration (FDA), to conduct a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, as well as the receipt of regulatory approval from France’s Ministry of Health to initiate a French multi-center study examining the use of Alpha DaRT alongside capecitabine in treating locally advanced pancreatic cancer in 40 patients who have responded or had stable disease with first-line FOLFIRINOX.

Pembrolizumab combination trial in patients with HNSCC – Interim Data as of Jan 9, 2025

The Company also announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, targeting a similar population as evaluated in Merck’s KEYNOTE-048 study9 and with a Combined Positive Score (CPS) of at least 1. As of Jan 9, 2025, eight patients were treated with Alpha DaRT and pembrolizumab in the study. Of the eight patients treated, three demonstrated a systemic complete response, three demonstrated a systemic partial response, and two patients died before being evaluated, demonstrating:

● 37.5% systemic complete response rate, compared to a systemic complete response rate of 5% observed in this population in the KEYNOTE-048 study

● 75% systemic ORR, compared to a systemic ORR of 19% observed in a comparable population in the KEYNOTE-048 study

An abstract entitled "Management of Metastatic Head and Neck Squamous Cell Carcinoma in Elderly Patients Using Diffusing Alpha-Emitter Radiation Therapy in Combination with Pembrolizumab," with interim data from this clinical study, has been accepted for presentation at the 11th European Congress on Head and Neck Oncology on March 26-29, 2025 in Amsterdam.

In addition, no SAEs related to Alpha DaRT treatment were reported in these patients as of the data cutoff date of January 9, 2025.

In today’s presentation, the clinicians will also review the case of a patient with HNSCC in the alveolar ridge and lip as well as dermal involvement, who underwent Alpha DaRT treatment of the neck alongside pembrolizumab, and has experienced a complete resolution of all tumors and no measurable disease over two years since treatment.

Following these strong results, the Company intends to discuss with the FDA a potential U.S. trial exploring the combination of Alpha DaRT and pembrolizumab in patients with head and neck cancer.

Additional Case Studies

During today’s R&D Update Day, clinicians will also present case studies from the first patients treated with Alpha DaRT in a number of other internal organs:

● In the first Alpha DaRT treatment of a patient with liver metastases from colorectal cancer, conducted as part of a two-stage hepatectomy, the clinicians observed a reduction of 18% in dimension of a treated lesion after one week, and at the same time also saw a reduction of over 25% in dimension of an untreated lesion elsewhere in the liver. The patient was discharged as planned and had an uneventful recovery. Histopathological analysis suggested a pronounced adaptive immune response in the treated lesion.

● In the first Alpha DaRT treatment delivered into a lung tumor, ten Alpha DaRT sources were delivered into a lymph node metastasis in the mediastinum, leading to a 41.6% reduction in volume after one month, and a 52.7% reduction in volume after two months, as well as a reduction in SUV uptake, with no treatment-related adverse events as of Jan 15, 2025.

● In the first Alpha DaRT treatment of rectal adenocarcinoma, a patient who declined to undergo abdominoperineal resection (APR surgery) and who instead received Alpha DaRT treatment, had a complete resolution of the tumor, with no self-reported bowel or bladder issues, and no treatment-related adverse events as of Jan 15, 2025.

Commentary

"Today is truly a momentous day for Alpha Tau," noted Alpha Tau CEO Uzi Sofer. "With these fantastic clinical results observed across a number of difficult cancers, we are now able to demonstrate the broader Alpha Tau vision: Beyond our historical activities treating patients with localized and unresectable tumors, we are now expanding our focus on treating internal organ tumors of high unmet need, as well as tumors in metastatic patients, by harnessing the potential systemic immune benefits of Alpha DaRT. We are incredibly excited to pursue treatment of these cancers further across a number of future clinical trials, with increased attention to launching U.S. clinical trials investigating Alpha DaRT treatment of the pancreas, the brain, and in combination with checkpoint inhibitors. We aim to continue to generate incredible results and hope for these patients of high unmet need."

Alpha Tau Virtual R&D Update Day

Alpha Tau will host a Virtual R&D Update Day featuring Prof. Aron Popovtzer, MD (Hadassah Medical Center), Corey Miller, MD, MSc (McGill University), Philip Blumenfeld, MD, MPH (Hadassah Medical Center), and Robert Den, MD (Alpha Tau) to discuss newly released data and case studies on Monday, January 27th, 2025 at 11:00am ET. To register for the event, click here: View Source A live question and answer session will follow the formal remarks.

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

On January 27, 2025 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in the upcoming investor relations events (Press release, Ideaya Biosciences, JAN 27, 2025, View Source [SID1234649897]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 35th Annual Healthcare Life Sciences Conference
Tuesday, February 11th, 2025 at 1:20 PM ET

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Matthew Biegler, Executive Director and Senior Analyst

Citi’s 2025 Virtual Oncology Leadership Summit
Wednesday, February 19th, 2025 at 12:00 PM ET

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst

A live audio webcast of the conference event, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at View Source and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.

Blacksmith Medicines to Present Preclinical Oncology Data at 8th DDR Inhibitors Summit

On January 27, 2025 Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, reported that it will present preclinical data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5’ DNA flaps during replication and repair, at the 8th DDR Inhibitors Summit taking place January 28th – 30th in Boston, MA (Press release, Blacksmith Medicines, JAN 27, 2025, View Source [SID1234649882]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to have the opportunity to present an update on our novel FEN1 inhibitor program at the DDR Inhibitor Summit," said Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith. "During the presentation we will highlight strong synergy between our novel FEN1 inhibitor and existing DDR drug classes underscoring its potential to enhance the therapeutic effects of existing DDR-targeting treatments."

Presentation details

Title: Novel FEN1 Inhibitor with Unique Metal-Binding Pharmacophore to Enhance Synergistic Therapeutic Effects with USP1, PARP, PARG, & ATR Inhibitors

Date/Time: January 30 @ 9:00am ET

Location: Hilton Boston Back Bay, Boston, MA

About FEN1

Flap endonuclease 1 (FEN1) is a structure-specific di-magnesium metallonuclease that cleaves 5’ DNA flaps during replication and repair. FEN1 is an attractive target for development of anticancer therapeutics because it is overexpressed in many tumor types and has a large number of synthetic lethality partners including genes in Homologous Recombination (HR) pathway.

About metalloenzymes and the Blacksmith platform

Metalloenzymes utilize a metal ion cofactor in the enzyme active site to perform essential biological functions. This diverse class of targets has historically been difficult to drug due to small molecule chemistry limitations that have plagued the industry. The Blacksmith metalloenzyme platform has solved this problem by leveraging the following:

A large proprietary fragment library of metal-binding pharmacophores (MBPs);
A comprehensive database containing a full characterization of the metalloenzyme genome including functions, metal cofactors, and associations to disease;
A first-of-its-kind metallo-CRISPR library of custom single guide RNAs;
An industry-leading metalloenzyme computational toolkit for docking, modeling and structure-based drug design; and
A robust and blocking intellectual property estate covering bioinorganic, medicinal, and computational chemistry approaches for metalloenzyme-targeted medicines.

Sapience Therapeutics Presents ST316 Phase 1 Dose Escalation Data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

On January 27, 2025 Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, reported that it presented Phase 1 safety and biomarker data on ST316, a novel peptide antagonist of β-catenin, during a poster session at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (GI) Cancers Symposium (Press release, Sapience Therapeutics, JAN 27, 2025, View Source [SID1234649898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ST316 is a first-in-class antagonist of β-catenin and its co-activator, BCL9, that is designed to selectively shut down the Wnt/β-catenin signaling pathway. The Phase 1 Dose Escalation study enrolled patients with advanced solid tumors likely to harbor abnormalities in the Wnt/β-catenin pathway to assess the safety, pharmacokinetics (PK), biomarker and preliminary activity of ST316, and to recommend a Phase 2 dose.

"With signals of anti-tumor activity, strong pharmacodynamic data, and a clean safety profile, we are pleased that the ST316 Phase 1 Dose Escalation study demonstrated clinical proof-of-concept as a single agent, in a patient population in which single agent response is limited," commented Dr. Abi Vainstein-Haras, Sapience’s Chief Medical Officer. "ST316’s tolerability as a single agent, together with the biomarker data from its Phase 1 study, are encouraging for its continued development in our ongoing Phase 2 Dose Expansion study, which is evaluating ST316 across multiple combinations and lines of treatment in colorectal cancer (CRC)."

Summary of Phase 1 Dose Escalation Results:

ST316 disrupts the interaction of β-catenin with BCL9 to result in Wnt/β-catenin pathway inhibition.
ST316 was shown to be safe and well tolerated at all doses tested.
The prolonged stable disease noted with single agent ST316 is consistent with early signals of anti-tumor activity.
ST316 demonstrates tumor uptake and target engagement, as shown by a shift in the localization of β-catenin from nucleus to cytoplasm/membrane following treatment in 4 of 7 patients assessed.
ST316 significantly reduced the expression of immunosuppressive polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in all Phase I patients that displayed elevated baseline levels (n=7).
Based on the safety and pharmacodynamic effects that are consistent with the mechanism of action, ST316 is now being tested in combination with chemotherapy in advanced colorectal cancer patients across different lines of treatment.
Poster Presentation:

Title: "Safety and biomarker assessment of ST316, a novel peptide antagonist of ß-catenin, in patients with advanced solid tumors"
Session: Poster Session C: Cancers of the Colon, Rectum and Anus
Date/Time: Saturday, January 25, 2025, 7:00 am to 7:55 am PST
Abstract Number: 286
Presenting Author: Anthony El-Khoueiry, MD

More information can be found on the ASCO (Free ASCO Whitepaper) GI website.

About ST316
ST316 is a first-in-class antagonist of the interaction between β-catenin and its co-activator, BCL9, a complex responsible for driving oncogene expression and immune exclusion in multiple cancers where aberrant Wnt/β-catenin pathway signaling is observed. ST316 exposure in cancer cells prevents BCL9-driven nuclear localization of β-catenin and inhibits formation of the Wnt enhanceosome protein complex. Disruption of this interaction selectively suppresses the transcription of oncogenic Wnt target genes that regulate proliferation, migration, invasion and the metastatic potential of tumor cells, as well as genes that regulate the immunosuppression of the tumor microenvironment. ST316 creates a pro-immune tumor microenvironment and in preclinical models has shown to be synergistic with checkpoint inhibition. Due to its selectivity and downstream modulation of the Wnt/β-catenin pathway, ST316 presents an opportunity to safely and effectively target Wnt/β-catenin driven pathologies without the toxicities previously seen with other Wnt pathway agents.

ST316-101 (NCT05848739) is a first-in-human, open-label, Phase 1-2 Dose Escalation and Expansion study designed to determine the safety, tolerability, PK, PD and early efficacy of ST316. The Phase 1 Dose Escalation portion of the study tested various dose levels of ST316 in patients with select advanced solid tumors that are known to harbor abnormalities of the Wnt/β-catenin signaling pathway, including CRC. ST316 is currently being tested in the Phase 2 portion of the study in CRC patients in combination with relevant standards of care and in multiple lines of treatment. The U.S. FDA has granted Orphan Drug Designation to ST316 for the treatment of familial adenomatous polyposis (FAP).

GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research

On January 27, 2025 GSK plc (LSE/NYSE: GSK) and the University of Oxford (Oxford) reported that they have entered a new research collaboration focused on the potential of cancer prevention through vaccination (Press release, GlaxoSmithKline, JAN 27, 2025, View Source [SID1234649883]). The GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational research, exploring precancer biology to generate key insights on how cancer develops in humans that could inform new approaches to cancer vaccination. GSK will invest up to £50 million over a minimum of three years to support this early research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evidence shows that most cancers take years or even decades to develop from normal cells to precancerous cells (or precancer) to cancer. Oxford University has world-leading expertise in the study of precancer biology including the identification and sequencing of neoantigens, or tumour-specific proteins that prompt the immune system to recognise cancer.1 This unique focus could help target the vulnerabilities of precancerous cells through an active intervention like a vaccine or targeted medicine to prevent them from progressing to cancer.

Tony Wood, Chief Scientific Officer, GSK, said: "We’re pleased to further strengthen our relationship with Oxford University and to combine the deep knowledge of Oxford and GSK scientists. By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer."

Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said: "This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide."

Science and Technology Secretary, Peter Kyle, said: "Cancer is a disease that has brought pain and heartbreak to every family in the country, including my own. But through our world-leading universities and businesses working in lockstep, like Oxford and GSK are doing here, we can harness science and innovation to transform what’s possible when it comes to diagnosing and treating this disease. As part of our Plan for Change, the Government is determined to back our £108 billion life sciences sector to deliver research like this – which could transform our health – whilst boosting our economy too."

Building on GSK’s ongoing relationship with Oxford, this collaboration will continue to combine GSK’s expertise in the science of the immune system and global development capability with Oxford’s cutting-edge research, clinical capabilities and world-leading scientists.

In 2021, GSK and Oxford established the Institute of Molecular and Computational Medicine. The Institute, based at the University of Oxford, has demonstrated progress at improving the success and speed of research and development of new medicines, specifically in the field of neurodegeneration, building on insights from human genetics and using advanced technologies such as functional genomics and machine learning.